Literature DB >> 18333037

Preoperative staging and evaluation of resectability in pancreatic ductal adenocarcinoma.

R Andersson1, C E Vagianos, R C N Williamson.   

Abstract

BACKGROUND: Cancer of the pancreas is a common disease, but the large majority of patients have tumours that are irresectable at the time of diagnosis. Moreover, patients whose tumours are clearly beyond surgical cure are best treated non-operatively, if possible, by relief of biliary obstruction and percutaneous biopsy to confirm the diagnosis and then consideration of oncological treatment, notably chemotherapy. These facts underline the importance of a standard protocol for the preoperative determination of operability (is it worth operating?) and resectability (is there a chance that the tumour can be removed?). Recent years have seen the advent of many new techniques, both radiological and endoscopic, for the diagnosis and staging of pancreatic cancer. It would be impracticable in time and cost to submit every patient to every test. This review will evaluate the available techniques and offer a possible algorithm for use in routine clinical practice. DISCUSSION: In deciding whether to operate with a view to resecting a pancreatic cancer, the surgeon must take into account factors related to the patient, the tumour and the institution and team entrusted with the patient's care. Patient-related factors include age, general health, pain and the presence or absence of malnutrition and an acute phase inflammatory response. Tumour-related factors include tumour size and evidence of spread, whether to adjacent organs (notably major blood vessels) or further afield. Hospital-related factors chiefly concern the volume of pancreatic cancer treated and thus the experience of the whole team. Determination of resectability is heavily dependent upon detailed imaging. Nowadays conventional ultrasonography can be supplemented by endoscopic, laparoscopic and intra-operative techniques. Computed tomography (CT) remains the single most useful staging modality, but MRI continues to improve. PET scanning may demonstrate unsuspected metastases and likewise laparoscopy. Diagnostic cholangiography can be performed more easily by MR techniques than by endoscopy, but ERCP is still valuable for preoperative biliary decompression in appropriate patients. The role of angiography has declined. Percutaneous biopsy and peritoneal cytology are not usually required in patients with an apparently resectable tumour. The prognostic value of tumour marker levels and bone marrow biopsy is yet to be established. Preoperative chemotherapy or chemoradiation may have a role in down-staging an irresectable tumour sufficiently to render it resectable. Selective use of diagnostic laparoscopy staging is potentially helpful in determination of resectability. Laparotomy remains the definitive method for determining the resectability of pancreatic cancer, with or without portal vein resection, and should be undertaken in suitable patients without clear-cut evidence of irresectability.

Entities:  

Year:  2004        PMID: 18333037      PMCID: PMC2020655          DOI: 10.1080/13651820310017093

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  74 in total

Review 1.  Pancreatic biopsy: why? When? How?

Authors:  I Ihse; J Axelson; S Dawiskiba; L Hansson
Journal:  World J Surg       Date:  1999-09       Impact factor: 3.352

Review 2.  Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma.

Authors:  N C Balci; R C Semelka
Journal:  Eur J Radiol       Date:  2001-05       Impact factor: 3.528

3.  Pain as a predictor of outcome in patients with operable pancreatic carcinoma.

Authors:  D P Kelsen; R Portenoy; H Thaler; Y Tao; M Brennan
Journal:  Surgery       Date:  1997-07       Impact factor: 3.982

Review 4.  Preoperative combined modality therapy for pancreatic cancer.

Authors:  T A Rich; D B Evans
Journal:  World J Surg       Date:  1995 Mar-Apr       Impact factor: 3.352

5.  Positive peritoneal cytology predicts unresectability of pancreatic adenocarcinoma.

Authors:  N B Merchant; K C Conlon; P Saigo; E Dougherty; M F Brennan
Journal:  J Am Coll Surg       Date:  1999-04       Impact factor: 6.113

Review 6.  Laparoscopy in the staging of pancreatic cancer.

Authors:  P W Pisters; J E Lee; J N Vauthey; C Charnsangavej; D B Evans
Journal:  Br J Surg       Date:  2001-03       Impact factor: 6.939

7.  Experience with laparoscopic ultrasonography for defining tumour resectability in carcinoma of the pancreatic head and periampullary region.

Authors:  A M Taylor; S A Roberts; J M Manson
Journal:  Br J Surg       Date:  2001-08       Impact factor: 6.939

8.  Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region.

Authors:  J H Allema; M E Reinders; T M van Gulik; M J Koelemay; D J Van Leeuwen; L T de Wit; D J Gouma; H Obertop
Journal:  Cancer       Date:  1995-04-15       Impact factor: 6.860

9.  Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group.

Authors:  J P Neoptolemos; R C Russell; S Bramhall; B Theis
Journal:  Br J Surg       Date:  1997-10       Impact factor: 6.939

10.  Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT.

Authors:  Wolfgang Schima; Reinhold Függer; Ewald Schober; Claudia Oettl; Peter Wamser; Florian Grabenwöger; J Mark Ryan; Gottfried Novacek
Journal:  AJR Am J Roentgenol       Date:  2002-09       Impact factor: 3.959

View more
  21 in total

1.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

Review 2.  Borderline resectable pancreatic cancer: definitions and management.

Authors:  Nicole E Lopez; Cristina Prendergast; Andrew M Lowy
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Can pancreaticoduodenectomy be used to palliate selective metastatic malignancies? Case report of malignant fibrous histiocytoma.

Authors:  Mindy M Ho; Thomas J Howard; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

4.  Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma.

Authors:  Shun Zhang; Yi-Ming Wang; Chuan-Dong Sun; Yun Lu; Li-Qun Wu
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

5.  Predicting distant metastasis in patients with suspected pancreatic and periampullary tumors for selective use of staging laparoscopy.

Authors:  Annelie Slaar; Wietse J Eshuis; Niels A van der Gaag; C Yung Nio; Olivier R C Busch; Thomas M van Gulik; Johannes B Reitsma; Dirk J Gouma
Journal:  World J Surg       Date:  2011-11       Impact factor: 3.352

Review 6.  Multidisciplinary management of locally advanced-borderline resectable adenocarcinoma of the head of the pancreas.

Authors:  F Calvo; C Guillen Ponce; M Muñoz Beltran; A Sanjuanbenito Dehesa
Journal:  Clin Transl Oncol       Date:  2012-11-21       Impact factor: 3.405

7.  Imaging of pancreatic cancer: An overview.

Authors:  Pavan Tummala; Omer Junaidi; Banke Agarwal
Journal:  J Gastrointest Oncol       Date:  2011-09

8.  Diagnosis, Preoperative Evaluation, and Assessment of Resectability of Pancreatic and Periampullary Cancer.

Authors:  Ashish Verma; Sunit Shukla; Nimisha Verma
Journal:  Indian J Surg       Date:  2015-10-08       Impact factor: 0.656

9.  Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.

Authors:  Hyunki Kim; Christopher J Rigell; Guihua Zhai; S Kyle Lee; Sharon L Samuel; Amber Martin; Heidi R Umphrey; Cecil R Stockard; T Mark Beasley; Donald J Buchsbaum; Long Shan Li; David A Boothman; Kurt R Zinn
Journal:  Mol Imaging Biol       Date:  2013-07-09       Impact factor: 3.488

10.  [Pylorus-preserving pancreatic head resection: a new standard for tumors].

Authors:  M Glanemann; M Bahra; P Neuhaus
Journal:  Chirurg       Date:  2008-12       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.